Lightlake Therapeutics Appoints Professor Martin Wilkins Medical Advisor
24 Februar 2011 - 3:20PM
Marketwired
Lightlake Therapeutics Inc. ("Lightlake") (OTCBB: LLTP) is pleased
to announce the appointment of Professor Martin Wilkins as Medical
Advisor, as Lightlake continues to build a world-class advisory
panel.
Martin R. Wilkins is the Professor of Clinical Pharmacology and
Head of the Division of Experimental Medicine, Imperial College
London and Director of Clinical and Investigative Sciences within
Imperial College Healthcare NHS Trust. He is a Consultant Physician
within Imperial College Healthcare NHS Trust and has been the
Director of the Sir John McMichael Centre for Clinical Research at
Hammersmith Hospital since its establishment in 2001.
Professor Wilkins is a clinician scientist with a background in
clinical pharmacology and toxicology. His primary interest is in
proof-of-concept studies in humans.
He directs an internationally competitive research program in
pulmonary hypertension from basic science to clinical trials,
publishing regularly in peer-reviewed journals. His work is funded
by grants from the Wellcome Trust, Medical Research Council and The
British Heart Foundation.
The Division of Experimental Medicine hosts the Wellcome Trust -
GSK Translational Medicine Fellowship Programme at Imperial
College.
Dr Michael Sinclair, Chairman of Lightlake Therapeutics
commented: 'Professor Wilkins brings the ability to bridge the gap
between academic studies, and clinical development.'
'He leads a unit with an international reputation, within a
world-class institution, which will be one of the main centres for
our Phase III trial.'
About Lightlake Therapeutics
Lightlake Therapeutics is an early stage biopharmaceutical
company aiming to build a solid platform of pharmacological
treatments based on our expertise using opioid antagonists.
Significant developments include the use of an opioid antagonist
nasal spray to address binge-eating obesity. A Phase II trial of
this product in Helsinki is due to be completed during 2011.
This press release contains forward-looking statements. These
statements relate to future events or our future financial
performance and involve known and unknown risks, uncertainties and
other factors that may cause our or our industry's actual results,
levels of activity, performance or achievements to be materially
different from any future results, levels of activity, performance
or achievements expressed, implied or inferred by these
forward-looking statements. In some cases, you can identify
forward-looking statements by terminology such as "may", "will",
"should", "could", "would", "expects", "plans", "intends",
"anticipates", "believes", "estimates", "predicts", "projects",
"potential" or "continue" or the negative of such terms and other
comparable terminology. These statements are only predictions based
on our current expectations and projections about future events.
You should not place undue reliance on these statements. Actual
events or results may differ materially. In evaluating these
statements, you should specifically consider various factors. These
and other factors may cause our actual results to differ materially
from any forward-looking statement. We undertake no obligation to
update any of the forward-looking statements after the date of this
presentation to conform those statements to reflect the occurrence
of unanticipated events, except as required by applicable law.
Add to Digg Bookmark with del.icio.us Add to Newsvine
Contacts: Lightlake Therapeautics Inc. Dr Roger Crystal CEO
roger.crystal@lightlake.fi Lightlake Therapeautics Inc. Dr Michael
Sinclair Chairman michael.sinclair@lightlake.fi www.lightlake.org
Press Inquiries: TypeA Consulting, Inc. Christine Barisheff
Christine@typeaconsult.com
Opiant Pharmaceuticals (NASDAQ:OPNT)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Opiant Pharmaceuticals (NASDAQ:OPNT)
Historical Stock Chart
Von Jul 2023 bis Jul 2024